SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - PHARMABIZ.COM - A la Une - 03/Sep 00:00
Nxera Pharma to get US$ 35 mn from Neurocrine for successful completion of phase 2 trial with NBI─1117568 in adults with schizophrenia
Nxera Pharma Co., Ltd.(formerly known as Sosei Group or Sosei Heptares), announces that it will receive a US$ 35 million payment from Neurocrine Biosciences (Neurocrine), triggered by the successful
Articles similaires
Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma
pharmabiz.com - 14/Sep 23:19
Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
drugs.com - 05/Sep 05:09
BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30
drugs.com - 11:09
HONG KONG, Sept. 17, 2024. Ascletis Pharma Inc. ("Ascletis") announces today completion of initial dosing in its two recently initiated U.S. Phase I...
Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 | Companies includes Adamas Pharmaceuticals, Acorda Therapeutics, Impel NeuroPharma, Neurocrine Biosciences, Kyowa Kirin, Sunovion Pharma
mountaintoday.in - 12/Sep 08:52
Levodopa-induced Dyskinesia Market DelveInsight’s analysts project market growth, fueled by increasing prevalence, improved diagnostics,...
Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 | Companies includes Adamas Pharmaceuticals, Acorda Therapeutics, Impel NeuroPharma, Neurocrine Biosciences, Kyowa Kirin, Sunovion Pharma
mountaintoday.in - 12/Sep 08:52
Levodopa-induced Dyskinesia Market DelveInsight’s analysts project market growth, fueled by increasing prevalence, improved diagnostics,...
Telesales Team Lead at LemFi (Formerly Lemonade Finance) September, 2024
theparadise.ng - 14/Sep 15:35
Never pay for any CBT, test or assessment as part of any recruitment process. When in doubt, contact us Lemonade Finance (YC S21) is building a...
Les derniers communiqués
-
Aucun élément